| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Rezolute, Inc. | Director | Common Shares | 55,500 | $510,045 | $9.19 | 19 Nov 2025 | Direct |
| Rezolute, Inc. | Director | Common Shares | 53,572 | $492,326 | $9.19 | 19 Nov 2025 | The Labrucherie Trust dated 9/1/2009 |
| ACELYRIN, Inc. | CFO and CBO | Common Stock | 40,763 | $301,932 | $7.41 | 04 Oct 2023 | Indirect |
| Septerna, Inc. | Chief Financial Officer | Common Stock | 40,000 | $234,000 | $5.85 | 27 Feb 2025 | By Trust |
| NEKTAR THERAPEUTICS | SVP, COO & CFO | Common Stock | 312,905 | $153,323 | $0.49 | 16 May 2022 | Direct |
| ACELYRIN, Inc. | CFO and CBO | Common Stock | 6,250 | $46,294 | $7.41 | 04 Oct 2023 | Direct |
| ACELYRIN, Inc. | CFO and CBO | Employee Stock Option (right to buy) | 184,042 | 23 May 2024 | Direct | ||
| ACELYRIN, Inc. | CFO and CBO | Employee Stock Option (right to buy) | 150,000 | 31 Aug 2024 | Direct | ||
| Septerna, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 37,500 | 07 Aug 2025 | Direct | ||
| Rezolute, Inc. | Director | Director Stock Option (Right to Buy) | 12,000 | 19 Nov 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| RZLT | Rezolute, Inc. | 19 Nov 2025 | 2 | $0 | 4 | Director | 21 Nov 2025, 16:36 |
| SEPN | Septerna, Inc. | 07 Aug 2025 | 1 | $0 | 4 | Chief Financial Officer | 11 Aug 2025, 19:06 |
| RZLT | Rezolute, Inc. | 10 Jun 2025 | 2 | $0 | 4 | Director | 13 Jun 2025, 14:15 |
| SEPN | Septerna, Inc. | 25 Feb 2025 | 2 | $56,866 | 4 | Chief Financial Officer | 27 Feb 2025, 18:51 |
| SEPN | Septerna, Inc. | 19 Feb 2025 | 3 | $172,296 | 4 | Chief Financial Officer | 21 Feb 2025, 18:06 |
| RZLT | Rezolute, Inc. | 16 Feb 2025 | 2 | $0 | 4 | Director | 20 Feb 2025, 11:10 |
| SEPN | Septerna, Inc. | 07 Feb 2025 | 1 | $0 | 4 | Chief Financial Officer | 07 Feb 2025, 16:37 |
| SEPN | Septerna, Inc. | 06 Jan 2025 | 0 | $0 | 3 | Chief Financial Officer | 07 Jan 2025, 17:09 |
| SLRN | ACELYRIN, Inc. | 31 Aug 2024 | 1 | $0 | 4 | CFO and CBO | 04 Sep 2024, 20:36 |
| SLRN | ACELYRIN, Inc. | 23 May 2024 | 1 | $0 | 4 | CFO and CBO | 24 May 2024, 18:59 |
| RZLT | Rezolute, Inc. | 23 Jan 2024 | 1 | $0 | 4 | Director | 25 Jan 2024, 12:08 |
| SLRN | ACELYRIN, Inc. | 09 Jan 2024 | 1 | $0 | 4 | Chief Financial Officer | 11 Jan 2024, 18:26 |
| SLRN | ACELYRIN, Inc. | 04 Oct 2023 | 1 | $0 | 4 | Chief Financial Officer | 06 Oct 2023, 17:53 |
| SLRN | ACELYRIN, Inc. | 17 Aug 2023 | 1 | $0 | 4 | Chief Financial Officer | 21 Aug 2023, 16:48 |
| SLRN | ACELYRIN, Inc. | 02 Aug 2023 | 0 | $0 | 3 | Interim CFO | 03 Aug 2023, 20:08 |
| RZLT | Rezolute, Inc. | 23 Jun 2022 | 1 | $0 | 4 | Director | 27 Jun 2022, 17:43 |
| NKTR | NEKTAR THERAPEUTICS | 15 May 2022 | 2 | -$68,919 | 4 | SVP, COO & CFO | 17 May 2022, 21:32 |
| RZLT | Rezolute, Inc. | 04 May 2022 | 1 | $199,997 | 4/A | Director | 09 May 2022, 16:28 |
| NKTR | NEKTAR THERAPEUTICS | 16 Feb 2022 | 1 | -$82,990 | 4 | SVP, COO & CFO | 18 Feb 2022, 17:14 |
| NKTR | NEKTAR THERAPEUTICS | 16 Dec 2021 | 2 | $0 | 4 | SVP, COO & CFO | 20 Dec 2021, 19:23 |
| NKTR | NEKTAR THERAPEUTICS | 16 Nov 2021 | 2 | -$316,390 | 4 | SVP, COO & CFO | 18 Nov 2021, 17:06 |
| NKTR | NEKTAR THERAPEUTICS | 15 Nov 2021 | 0 | $0 | 4/A | SVP, COO & CFO | 20 Dec 2021, 19:22 |
| NKTR | NEKTAR THERAPEUTICS | 12 Oct 2021 | 1 | $0 | 4 | SVP, COO & CFO | 14 Oct 2021, 21:05 |
| NKTR | NEKTAR THERAPEUTICS | 16 Aug 2021 | 2 | -$149,480 | 4 | SVP, COO & CFO | 18 Aug 2021, 18:58 |
| RZLT | Rezolute, Inc. | 14 Jun 2021 | 1 | $0 | 4 | Director | 14 Jul 2021, 21:03 |
| NKTR | NEKTAR THERAPEUTICS | 17 May 2021 | 1 | -$144,533 | 4 | SVP, COO & CFO | 19 May 2021, 19:04 |